CSIMarket
 


Generation Bio Co   (GBIO)
Other Ticker:  
 
 

GBIO's Capital Expenditures Growth by Quarter and Year

Generation Bio Co 's Capital Expenditures results by quarter and year




GBIO Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 4.58 0.68 2.84 1.79
III Quarter September 0.61 0.65 0.94 1.50
II Quarter June 1.45 4.68 1.27 2.22
I Quarter March 0.76 2.78 0.92 0.00
FY   7.40 8.79 5.97 5.51



GBIO Capital Expenditures fourth quarter 2023 Y/Y Growth Comment
Generation Bio Co achieved in the fourth quarter 2023, above Company average Capital Expenditures surge of 573.53% year on year, to $ 4.58 millions.

Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 33 other companies have achieved higher Capital Expenditures growth. While Generation Bio Co ' s Capital Expenditures doubling of 573.53% ranks overall at the positon no. 1052 in the fourth quarter 2023.




GBIO Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December 573.53 % -76.06 % 58.66 % -
III Quarter September -6.15 % -30.85 % -37.33 % -
II Quarter June -69.02 % 268.5 % -42.79 % -
I Quarter March -72.66 % 202.17 % - -
FY   -15.81 % 47.24 % 8.35 % -

Financial Statements
Generation Bio Co 's fourth quarter 2023 Capital Expenditures $ 4.58 millions GBIO's Income Statement
Generation Bio Co 's fourth quarter 2022 Capital Expenditures $ 0.68 millions Quarterly GBIO's Income Statement
New: More GBIO's historic Capital Expenditures Growth >>


GBIO Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December 650.82 % 4.62 % 202.13 % 19.33 %
III Quarter September -57.93 % -86.11 % -25.98 % -32.43 %
II Quarter June 90.79 % 68.35 % 38.04 % -
I Quarter March 11.76 % -2.11 % -48.6 % -
FY (Year on Year)   -15.81 % 47.24 % 8.35 % -




Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #34
Healthcare Sector #124
Overall #1052

Capital Expenditures Y/Y Growth Statistics
High Average Low
122.78 % 16.43 % -68.51 %
(Sep 30 2022)   (Jun 30 2023)
Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #34
Healthcare Sector #124
Overall #1052
Capital Expenditures Y/Y Growth Statistics
High Average Low
122.78 % 16.43 % -68.51 %
(Sep 30 2022)   (Jun 30 2023)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Generation Bio Co 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
650.82 % 59.52 % -86.1 %
(Dec 31 2023)  


GBIO's IV. Quarter Q/Q Capital Expenditures Comment
Generation Bio Co achieved in the IV. Quarter 2023 above company average sequential Capital Expenditures doubling of 650.82%, to $ 4.58 millions, from $0.61 millions in the third quarter.
Generation Bio Co is impressively improving, with reporting above regular gain, but also increasing pace, Christian White, Major Pharmaceutical Preparations industry contributor mentioned.

Within Major Pharmaceutical Preparations industry Generation Bio Co achieved highest sequential Capital Expenditures growth. While Generation Bio Co 's Capital Expenditures growth quarter on quarter, overall rank is 25.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #1
Healthcare Sector #3
Overall #25
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #1
Healthcare Sector #3
Overall #25
Capital Expenditures Q/Q Growth Statistics
High Average Low
650.82 % 59.52 % -86.1 %
(Dec 31 2023)  


GBIO's IV. Quarter Q/Q Capital Expenditures Comment
Generation Bio Co achieved in the IV. Quarter 2023 above company average sequential Capital Expenditures doubling of 650.82%, to $ 4.58 millions, from $0.61 millions in the third quarter.
GBIO is going from strength to strength, with recording above normal growth, but also improving speed, Christian White, Major Pharmaceutical Preparations industry contributor added.

Within Major Pharmaceutical Preparations industry Generation Bio Co achieved highest sequential Capital Expenditures growth. While Generation Bio Co 's Capital Expenditures growth quarter on quarter, overall rank is 25.


Generation Bio Co 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Capital Expenditures 12 Months Ending $ 7.40 $ 3.50 $ 3.54 $ 6.77 $ 8.80
Y / Y Capital Expenditures Growth (TTM) -15.95 % -68.06 % -68.51 % -13.48 % 47.72 %
Year on Year Capital Expenditures Growth Overall Ranking # 219 # 151 # 49 # 8 # 14
Seqeuential Capital Expenditures Change (TTM) 111.4 % -1.16 % -47.73 % -23.05 % -19.65 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 1052 # 1115 # 164 # 771 # 938




Cumulative Capital Expenditures growth Comment
Generation Bio Co showed decline, but improvement compare to trailing twelve month Capital Expenditures decrease in Sep 30 2023. If the fiscal year would end in Dec 31 2023, Generation Bio Co 's annual Capital Expenditures fall would be -15.95% year on year to $7 millions.

Within the Healthcare sector 29 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 151 to 219.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
122.78 %
16.43 %
-68.51 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 34
Healthcare Sector # 30
Overall # 219

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
122.78 %
16.43 %
-68.51 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 34
Sector # 124
S&P 500 # 1052
Cumulative Capital Expenditures growth Comment
Generation Bio Co showed decline, but improvement compare to trailing twelve month Capital Expenditures decrease in Sep 30 2023. If the fiscal year would end in Dec 31 2023, Generation Bio Co 's annual Capital Expenditures drop would be -15.95% year on year to $7 millions.

Within the Healthcare sector 29 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 151 to 219.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
122.78 %
16.43 %
-68.51 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 34
Healthcare Sector # 30
Overall # 219

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
122.78 %
16.43 %
-68.51 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 34
Sector # 124
S&P 500 # 1052




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
GBIO's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for GBIO's Competitors
Capital Expenditures Growth for Generation Bio Co 's Suppliers
Capital Expenditures Growth for GBIO's Customers

You may also want to know
GBIO's Annual Growth Rates GBIO's Profitability Ratios GBIO's Asset Turnover Ratio GBIO's Dividend Growth
GBIO's Roe GBIO's Valuation Ratios GBIO's Financial Strength Ratios GBIO's Dividend Payout Ratio
GBIO's Roa GBIO's Inventory Turnover Ratio GBIO's Growth Rates GBIO's Dividend Comparisons



Companies with similar Capital Expenditures drop for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Dec 31 2023
Aadi Bioscience Inc 946.15%$ 946.154 millions
Procept Biorobotics Corporation906.35%$ 906.351 millions
Moonlake Immunotherapeutics720.22%$ 720.224 millions
Exelixis Inc 665.00%$ 664.997 millions
Utah Medical Products Inc626.32%$ 626.316 millions
Alpha Tau Medical Ltd 608.08%$ 608.075 millions
Vericel Corporation596.44%$ 596.444 millions
Generation Bio Co 571.55%$ 571.554 millions
Zynex inc 569.77%$ 569.767 millions
Eyenovia inc 368.64%$ 368.638 millions
Harvard Bioscience Inc351.49%$ 351.489 millions
Urogen Pharma Ltd 330.77%$ 330.769 millions
Hims and Hers Health Inc 328.55%$ 328.550 millions
Masimo Corp295.31%$ 295.313 millions
Axonics Inc 290.15%$ 290.149 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com